Global Leading Market Research Publisher QYResearch announces the release of its latest report “Conventional Hard Gelatin Capsules – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Conventional Hard Gelatin Capsules market, including market size, share, demand, industry development status, and forecasts for the next few years.
Market Overview: The Enduring Foundation of Oral Dosage Forms
For pharmaceutical executives, nutraceutical manufacturers, contract manufacturing organizations (CMOs), and healthcare investors, conventional hard gelatin capsules represent one of the most established and reliable drug delivery platforms in the industry. Despite the emergence of alternative capsule technologies (hypromellose capsules, soft gelatin capsules, tablet formulations), conventional hard gelatin capsules maintain significant market share due to their proven stability, cost-effectiveness, and consumer acceptance. The global market for Conventional Hard Gelatin Capsules was estimated to be worth US$ 2,974 million in 2025 and is projected to reach US$ 4,504 million by 2032, growing at a compound annual growth rate (CAGR) of 6.2% from 2026 to 2032. This steady expansion reflects sustained demand from pharmaceutical companies, dietary supplement manufacturers, and the cosmetics industry, particularly in emerging markets where generic drug production and nutraceutical consumption are accelerating.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6087435/conventional-hard-gelatin-capsules
Understanding Conventional Hard Gelatin Capsules: Composition and Function
Conventional hard gelatin capsules are solid dosage forms composed of two co-axial cylindrical shells (a cap and a body) made from gelatin, a protein derived from animal sources (such as bovine or porcine skin and bones). They are designed to enclose powdered, granular, or small pellet formulations of pharmaceutical drugs, dietary supplements, or other ingredients. The capsules are typically tasteless, odorless, and dissolvable in the gastrointestinal tract, allowing for the controlled release of the encapsulated content.
The key attributes that sustain conventional hard gelatin capsules as a preferred dosage form include:
- Taste and odor masking – The gelatin shell effectively masks bitter or unpleasant tastes and odors of active pharmaceutical ingredients (APIs), improving patient compliance, particularly in pediatric and geriatric populations.
- Rapid dissolution – Hard gelatin capsules typically disintegrate within 5–15 minutes in gastric fluid, enabling rapid API release and absorption. This is faster than many compressed tablets, which may require 30–60 minutes for complete disintegration.
- Dosage flexibility – Capsules can be filled with powders, granules, pellets, or even small tablets (capsule-in-capsule technology), accommodating a wide range of API physical properties and release profiles.
- Low moisture content – Hard gelatin shells typically contain 13–16% moisture, making them suitable for moisture-sensitive APIs that would degrade in aqueous-based formulations.
- Ease of manufacturing – Capsule filling is generally simpler and requires fewer processing steps than tablet compression, reducing capital equipment costs and validation requirements.
Gelatin sourcing considerations: The quality of hard gelatin capsules depends significantly on raw material selection. Bovine gelatin (derived from cow hides and bones) is the most common source globally, preferred for its consistent gel strength (Bloom value) and favorable regulatory status in most markets. Porcine gelatin (derived from pig skin) is also widely used, particularly in markets without religious restrictions (non-Halal, non-Kosher). Mixed gelatin capsules combine bovine and porcine sources to achieve specific performance characteristics. Regulatory labeling requirements for gelatin source identification have increased in recent years, particularly for markets with religious dietary requirements (Halal certification requires bovine or fish-derived gelatin; Kosher certification requires specific sourcing and processing oversight).
Market Segmentation: Key Players and Competitive Landscape
The Conventional Hard Gelatin Capsules market is segmented as below across a consolidated competitive landscape dominated by specialized gelatin and capsule manufacturers.
Global Gelatin and Capsule Leaders: Rousselot (part of Darling Ingredients, global gelatin leader with production facilities across Europe, Americas, and Asia), Gelita (German gelatin manufacturer, premium pharmaceutical-grade gelatin), PB Gelatins (Belgium-based, part of Tessenderlo Group), Sterling Gelatin (India, significant Asia-Pacific presence), Gelnex (Brazil, Latin American leader), Weishardt Group (France, specialty gelatin for pharmaceutical applications), Jellice Group (Japan, Asia-Pacific focused), Qinghai Gelatin (China, major domestic producer), GELCO (Egypt, Middle East and Africa presence), Geltech (Korea), Nitta Gelatin (Japan, pharmaceutical and food applications), Yasin Gelatin (Pakistan), Narmada Gelatines (India), and India Gelatine & Chemicals (India).
Segment by Type (Gelatin Source): The market is categorized into Bovine Gelatin Capsules (largest segment, approximately 55–60% of market revenue, driven by broad regulatory acceptance and availability), Porcine Gelatin Capsules (approximately 20–25%, preferred in markets without Halal/Kosher restrictions and where specific gel strength characteristics are required), Mixed Gelatin Capsules (approximately 10–15%, formulated to achieve specific performance properties such as customized dissolution profiles or improved mechanical strength), and Other (including fish-derived gelatin for Halal/Kosher compliance and emerging alternative sources).
Segment by Application: The market serves Pharmaceutical Companies (largest segment, approximately 60–65% of market revenue, including prescription drugs, over-the-counter medications, and generic pharmaceuticals), Nutrients and Health Products Companies (dietary supplements, vitamins, minerals, herbal products – fastest-growing segment, projected 8–10% CAGR), Cosmetics (encapsulated active ingredients for topical or oral beauty products – small but growing), and Other (veterinary pharmaceuticals, industrial applications).
Market Analysis: Key Trends Driving the 6.2% CAGR
Trend 1: Generic Drug Expansion Driving Capsule Demand in Emerging Markets
The global generic pharmaceutical market continues to expand, driven by patent expirations for branded drugs and healthcare system efforts to control costs. According to data cross-validated from corporate annual reports (Teva, Sandoz, Viatris 2025 filings) and government procurement databases (US FDA Orange Book, China NMPA approvals), hard gelatin capsules are the preferred dosage form for approximately 25–30% of generic oral solid drugs, particularly for APIs with poor compressibility (cannot be tableted) or those requiring taste masking.
For pharmaceutical executives and CMOs, the implication is sustained baseline demand for conventional hard gelatin capsules, with particular growth in Asia-Pacific, Latin America, and Africa where generic drug market penetration is increasing.
Recent data (last 6 months): China’s National Medical Products Administration (NMPA) approved 1,245 generic drug applications in 2025 (annual report, January 2026), of which 342 (27.5%) were capsule formulations. This represents a 15% year-over-year increase in generic capsule approvals, reflecting both expanded manufacturing capacity and regulatory efficiency improvements.
Trend 2: Nutraceutical and Dietary Supplement Growth – The Capsule Format Advantage
The dietary supplement industry has increasingly favored hard gelatin capsules over tablets for several reasons: capsules require fewer excipients (binders, fillers, lubricants) than tablets, making them attractive for “clean label” products; capsules can accommodate higher API load per unit (up to 800 mg in standard size 00 capsules versus 500–600 mg for tablets of equivalent size); and capsules are perceived by consumers as more “natural” than compressed tablets.
Market data: According to QYResearch supplement database, hard gelatin capsules account for approximately 40% of global dietary supplement unit volume (excluding liquids and powders), with the segment growing at 7.5% CAGR versus 4.2% for supplement tablets.
Exclusive industry observation: A notable divergence exists between vitamin/mineral supplements (where tablets remain strong due to lower cost per unit) and botanical/herbal supplements (where capsules dominate due to taste masking requirements and perceived authenticity). For capsule manufacturers, targeting botanical supplement contract manufacturers represents a higher-growth sub-segment than vitamin manufacturers.
Trend 3: Halal and Kosher Certification Requirements Reshaping Sourcing
Religious dietary requirements increasingly influence gelatin sourcing decisions, particularly in markets with large Muslim or Jewish populations. Halal certification requires gelatin from bovine sources (Halal-slaughtered cattle) or fish; porcine gelatin is prohibited. Kosher certification requires gelatin from bovine sources processed under rabbinical supervision.
Regional implications: Southeast Asia (Indonesia, Malaysia, Brunei – combined population 350+ million Muslims) has strict Halal requirements for pharmaceutical and supplement capsules. Manufacturers exporting to these markets must maintain Halal-certified supply chains and segregated production facilities. This has created a premium segment for bovine gelatin capsules, with prices 10–15% higher than conventional porcine or non-certified bovine capsules.
For marketing executives and supply chain directors, Halal certification is not merely a compliance issue but a market access requirement in fast-growing Southeast Asian markets. Companies without Halal-certified production lines are effectively excluded from government tenders and major retail channels in these countries.
Trend 4: Alternative Capsule Technologies – Limited Impact on Conventional Segment
Hypromellose (HPMC) capsules (plant-derived, vegetarian/vegan) have gained market share since their introduction, particularly in Western markets with growing vegetarian and vegan populations. However, the impact on conventional hard gelatin capsules has been limited for several reasons:
- Cost differential – HPMC capsules cost 20–40% more than conventional gelatin capsules, a significant consideration for price-sensitive generic drug and bulk supplement manufacturers.
- Dissolution characteristics – HPMC capsules may exhibit slower disintegration in acidic gastric conditions, affecting bioavailability for certain APIs. Regulatory submissions for HPMC capsule formulations require additional dissolution testing compared to gelatin capsules.
- Manufacturing compatibility – Existing capsule filling equipment generally handles both gelatin and HPMC capsules, but HPMC capsules are more brittle and require stricter humidity control during processing.
Market share data: QYResearch estimates that conventional hard gelatin capsules represented 82% of global capsule market revenue in 2025, down from 88% in 2015. The compound annual decline of 0.6 percentage points per year is gradual, with conventional capsules remaining the dominant format for the foreseeable future.
Trend 5: Manufacturing Efficiency and Quality Standardization
The conventional hard gelatin capsule industry has seen significant manufacturing efficiency improvements over the past decade, including:
- High-speed filling equipment – Modern capsule fillers operate at 100,000–200,000 capsules per hour (versus 30,000–50,000 per hour in 2000), reducing unit labor costs.
- In-line weight monitoring – Automated checkweighers and rejection systems reduce fill weight variability, improving product consistency and reducing waste.
- Traceability systems – Serialization and track-and-trace requirements (pharmaceutical serialization mandates in US (DSCSA), EU (FMD), China) have been implemented across capsule packaging lines.
For contract manufacturers and pharmaceutical companies, these efficiency gains have offset raw material price increases (gelatin prices have increased 2–4% annually over the past five years, driven by animal hide/skin supply constraints), stabilizing capsule filling prices for customers.
Technical constraint: Gelatin capsule shells are hygroscopic (absorb moisture from the environment). In high-humidity manufacturing environments (tropical climates, wet seasons), capsules may become soft and sticky, causing feeding and filling issues. Manufacturers in tropical regions (Southeast Asia, parts of India, Latin America) must invest in humidity-controlled production areas (dehumidifiers, air conditioning) to maintain year-round production capability. This capital requirement creates barriers to entry for small-scale manufacturers.
Industry Outlook and Strategic Implications
For pharmaceutical executives, nutraceutical manufacturers, capsule suppliers, and healthcare investors, several strategic imperatives emerge:
- For gelatin and capsule manufacturers: Invest in Halal/Kosher certification capabilities to access fast-growing Southeast Asian and Middle Eastern markets. Maintain quality consistency (gel strength, dissolution profile) as a competitive differentiator. Consider vertical integration (gelatin production to capsule manufacturing) to capture margin across the value chain.
- For pharmaceutical companies and CMOs: Evaluate capsule versus tablet decisions based on API characteristics (moisture sensitivity, compressibility, taste), not solely on historical preference. Maintain dual sourcing (multiple gelatin suppliers, multiple capsule vendors) to mitigate supply disruption risk.
- For nutraceutical brands: Leverage capsule format advantages (clean label, higher API load) in marketing communications. Consider Halal certification to access Muslim-majority markets.
- For healthcare investors: The 6.2% CAGR reflects stable, predictable demand from pharmaceutical and nutraceutical sectors. Monitor alternative capsule technology adoption rates (HPMC capsules) but recognize that conventional gelatin capsules will remain the dominant format through 2032 due to cost and performance advantages.
The complete QYResearch report provides granular 10-year forecasts by gelatin source (bovine, porcine, mixed, other), by application (pharmaceutical, nutraceutical, cosmetic), and by region, along with competitive positioning analysis based exclusively on audited corporate annual reports, official government statistics, and QYResearch’s proprietary primary research database.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
